Abstract:
Transient Tachypnea of the Newborn (TTN) is a prevalent cause of respiratory distress
in neonates, typically arising from delayed clearance of fetal lung fluid. Although
generally benign and self-limited, TTN can lead to significant morbidity, necessitating
interventions to reduce respiratory symptoms, hospital stays, and the need for oxygen
therapy [23,19]. The pathophysiology of TTN involves retained alveolar fluid, which
hampers effective gas exchange. Furosemide, a loop diuretic known for reducing
pulmonary edema, has been proposed as a potential treatment to enhance fluid
